IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in three major investor events in September 2025. The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3rd, host its 10-Year Anniversary R&D Day on September 8th featuring clinical data updates and KOL Dr. Arun D. Singh, and attend the Morgan Stanley Global Healthcare Conference on September 9th for one-on-one meetings.
The R&D Day will showcase multiple clinical data updates, outline future catalysts, and review long-term portfolio strategy. Live audio webcasts will be available on the company's investor relations website, with replays accessible for 30 days post-event.
IDEAYA Biosciences (NASDAQ: IDYA), azienda di medicina di precisione in oncologia, ha annunciato la partecipazione a tre importanti eventi per investitori a settembre 2025. La societ脿 sar脿 presente a un fireside chat al Cantor Global Healthcare Conference il 3 settembre, organizzer脿 il 10-Year Anniversary R&D Day l'8 settembre con aggiornamenti sui dati clinici e l'intervento del KOL Dr. Arun D. Singh, e parteciper脿 al Morgan Stanley Global Healthcare Conference il 9 settembre per incontri one-on-one.
Il R&D Day presenter脿 diversi aggiornamenti sui dati clinici, illustrer脿 i prossimi catalizzatori e analizzer脿 la strategia di portafoglio a lungo termine. Saranno disponibili webcast audio in diretta sul sito investor relations della societ脿, con le registrazioni accessibili per 30 giorni dopo l'evento.
IDEAYA Biosciences (NASDAQ: IDYA), compa帽铆a de medicina de precisi贸n en oncolog铆a, ha anunciado su participaci贸n en tres importantes eventos para inversores en septiembre de 2025. La empresa participar谩 en un fireside chat en el Cantor Global Healthcare Conference el 3 de septiembre, celebrar谩 su 10-Year Anniversary R&D Day el 8 de septiembre con actualizaciones de datos cl铆nicos y la participaci贸n del KOL Dr. Arun D. Singh, y asistir谩 al Morgan Stanley Global Healthcare Conference el 9 de septiembre para reuniones one-on-one.
El R&D Day mostrar谩 varias actualizaciones de datos cl铆nicos, se帽alar谩 los pr贸ximos catalizadores y revisar谩 la estrategia de cartera a largo plazo. Habr谩 webcasts de audio en directo en la web de relaciones con inversores de la compa帽铆a, con repeticiones disponibles durante 30 d铆as tras el evento.
IDEAYA Biosciences (NASDAQ: IDYA), 鞝曤皜鞚橅暀 旮半皹 膦呾枒頃� 須岇偓電� 2025雲� 9鞗旍棎 鞐措Μ電� 靹� 瓯挫潣 欤检殧 韴瀽鞛� 頄夓偓鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 9鞗� 3鞚� Cantor Global Healthcare Conference鞚� 韺岇澊鞏挫偓鞚措摐 毂楈棎 彀胳棳頃橁碃, 9鞗� 8鞚检棎電� 鞛勳儊 雿办澊韯� 鞐呺嵃鞚错姼鞕� KOL Dr. Arun D. Singh毳� 齑堨箔頃� 10-Year Anniversary R&D Day毳� 臧滌禍頃橂┌, 9鞗� 9鞚检棎電� Morgan Stanley Global Healthcare Conference鞐� 彀胳劃頃� 鞚茧寑鞚� 氙疙寘鞚� 歆勴枆頃╇媹雼�.
R&D Day鞐愳劀電� 雼れ垬鞚� 鞛勳儊 雿办澊韯� 鞐呺嵃鞚错姼毳� 瓿店皽頃橁碃 頄ロ泟 欤检殧 鞚措菠韸�(齑夒Г)毳� 鞝滌嫓頃橂┌ 鞛リ赴 韽姼韽措Μ鞓� 鞝勲灥鞚� 瓴�韱犿暊 鞓堨爼鞛呺媹雼�. 須岇偓鞚� 韴瀽鞛愱磤瓿� 鞗轨偓鞚错姼鞐愳劀 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓 膦呺 頉� 30鞚缄皠 鞛儩鞚� 鞝滉车頃� 鞓堨爼鞛呺媹雼�.
IDEAYA Biosciences (NASDAQ: IDYA), soci茅t茅 de m茅decine de pr茅cision en oncologie, a annonc茅 sa participation 脿 trois grands 茅v茅nements investisseurs en septembre 2025. La soci茅t茅 prendra part 脿 un fireside chat au Cantor Global Healthcare Conference le 3 septembre, organisera son 10-Year Anniversary R&D Day le 8 septembre avec des mises 脿 jour de donn茅es cliniques et l'intervention du KOL Dr. Arun D. Singh, et assistera au Morgan Stanley Global Healthcare Conference le 9 septembre pour des r茅unions individuelles.
Le R&D Day pr茅sentera plusieurs mises 脿 jour de donn茅es cliniques, exposera les prochains catalyseurs et passera en revue la strat茅gie de portefeuille 脿 long terme. Des webcasts audio en direct seront disponibles sur le site relations investisseurs de la soci茅t茅, avec des replays accessibles pendant 30 jours apr猫s l'茅v茅nement.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen f眉r pr盲zisionsmedizinische Onkologie, hat seine Teilnahme an drei wichtigen Investorenveranstaltungen im September 2025 angek眉ndigt. Das Unternehmen wird am 3. September an einem Fireside Chat auf der Cantor Global Healthcare Conference teilnehmen, veranstaltet am 8. September den 10-Year Anniversary R&D Day mit klinischen Datenaktualisierungen und dem KOL Dr. Arun D. Singh, und nimmt am 9. September an der Morgan Stanley Global Healthcare Conference f眉r Einzelgespr盲che teil.
Der R&D Day wird mehrere klinische Datenupdates vorstellen, zuk眉nftige Meilensteine skizzieren und die langfristige Portfolio-Strategie 眉berpr眉fen. Live-Audio-Webcasts sind auf der Investor-Relations-Website des Unternehmens verf眉gbar, Wiedergaben k枚nnen 30 Tage nach der Veranstaltung abgerufen werden.
- None.
- None.
Cantor Global Healthcare Conference 2025
Wednesday, September 3rd, 2025 at 9:10 AM ET
- Fireside chat with聽Yujiro S. Hata, President and Chief Executive Officer, hosted by聽Li Watsek, Director, Biotechnology Analyst
IDEAYA Biosciences 10-Year Anniversary R&D Day
Monday, September 8th, 2025 at 8:00 AM ET
- The Company will host an in-person and virtual R&D Day to share multiple clinical data updates across the pipeline, outline upcoming catalysts and key growth drivers, and review its long-term portfolio strategy.
- The event will feature key opinion leader (KOL) Dr. Arun D. Singh, Director of the Department of Ophthalmic Oncology at the Cole Eye Institute, Cleveland Clinic, who will join members of the company's leadership team.聽
Morgan Stanley 23rd Annual Global Healthcare Conference
Tuesday, September 9th, 2025
- Management will be participating in one-on-one investor meetings.
A live audio webcast of the conference events, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]
View original content to download multimedia:
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) 10-Year Anniversary R&D Day in 2025?
What will be presented at IDEAYA Biosciences' R&D Day 2025?
Where can I watch IDEAYA Biosciences' September 2025 investor presentations?
Which investor conferences is IDEAYA Biosciences (IDYA) attending in September 2025?
